Hybridan Small Cap Feast 14-09-2021

Focusrite 1715p £1bn (TUNE.L) The global music and audio products company supplying hardware and software used by professional and amateur musicians and the entertainment industry, updated the market on a positive trading year in which revenue, profits and cash flow have all grown substantially. As a result of this strong trading performance during the year, the Group now expects revenue for the financial year ending 31 August 2021 to be ahead of market expectations at approximately £173m, up f

Small Cap Feast: 20/05/21

What’s cooking in the IPO kitchen? Oxford Cannabinoid Technologies Holdings Plc to IPO onto the Standard List. They are a pre-revenue pharmaceutical company with an objective to develop cannabinoid-based prescription medicines approved by regulatory agencies including the US Food and Drug Administration, the European Medicines Agency, and the Medicines and Products Healthcare Regulatory Authority. Their drug development strategy includes the development of proprietary cannabinoid derivatives, n

SP Angel Healthcare Conditions- N4 Pharma (N4P.L): Update Note

SP Angel Healthcare Conditions

Novacyt S.A. (NCYT.L*): R&D Update | N4 Pharma (N4P.L): Full year results

SP Angel Healthcare Conditions

N4 Pharma (N4P.L): Patent Update

SP Angel Healthcare Condition

N4 Pharma (N4P.L): Placing to raise £2m | e-therapeutics (ETX.L): COVID-19 project update (from yesterday)

SP Angel Healthcare Conditions

N4 Pharma (N4P.L): Formulation update | Beximco Pharma (BXP.L): Appointment of Non-Executive Directors | Tekcapital PLC (TEK.LN): Belluscura Files 510(k) for XPLO2R™ Portable Oxygen Concentrator

SP Angel Healthcare Conditions- N4 Pharma (N4P.L): Initiation of Coverage

SP Angel Healthcare Conditions- 09-11-2020

SP Angel Healthcare Conditions- 05-11-2020

SP Angel Healthcare Conditions

Novacyt (NCYT.L): Interim results | N4 Pharma (N4P.L): Interim results

SP Angel Healthcare Conditions- 14-09-2020

SP Angel Healthcare Conditions

N4 Pharma (N4P.L): COVID-19 research project update | Silence Therapeutics (SLN.L): Half-year results

SP Angel Healthcare Conditions

N4 Pharma (N4P.L)*: Technology transfer and manufacturing contract

Initial Equity Trading Comments - 15 May 2023

LIBERUM: Aptamer* - Prelims supports growth projections

Kromek - Placing raises £7m with Open Offer of up to £1m

Kromek raised £7m (with up to £1m via an Open Offer) to strengthen the balance sheet and provide the working capital for the CT programme to bridge the gap before supply agreements with recently announced Tier 1 and Tier 2 OEMs commence in earnest. As the only independent commercial scale manufacturer of the next-generation detector (CZT) for use in CT and SPECT imaging systems, Kromek is actively engaged with 9 OEMs (both Tier 1 and Tier 2), with 3 agreements having now been signed (FC estimate

LIBERUM: Aptamer* - Initiation - Build better binders

Hybridan Small Cap Feast - 19 May 23

19th May 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv

Oxford BioDynamics+ (OBD, House Stock, 17p) - Expanding applications

Funding the opportunity in medical imaging

On 18 April Kromek announced a major seven-year agreement with a Tier 1 OEM to develop and incorporate its CZT-based detectors in the OEM’s advanced medical imaging scanners, and further deals have since followed. In order to fund these opportunities, on 5 May the Group announced a fund-raise of £8m (gross). It is our assumption that the Tier 1 OEM segment targeted is the CT scanner market. This was worth an estimated US$6.7bn in 2022 and, at a 5.6% CAGR, is expected to reach US$9.92bn by 2029.

NetScientific - FY 2022 results, portfolio value increases 35%

NetScientific, an investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies announces its FY 2022 results demonstrating a 35% increase in portfolio value to £41.8m across an expanding portfolio of 24 companies. NSCI reports that its portfolio has raised c. £70m. In line with its capital light investment strategy, NSCI/EMV have supported these fund-raises selectively through £3.2m of direct investments and loans, an

Destiny Pharma plc (DEST) - House Stock at 35p - Stars aligning

Initial Equity Trading Comments - 10 May 2023

Avon Protection - Termination of coverage

Edison Investment Research is terminating coverage on Avon Protection (AVON), Osirium Technologies (OSI), IQE (IQE), Kopy Goldfields (KOBY) and RhoVac (ROHVAC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

ReNeuron Group - Full steam ahead with CustomEx

ReNeuron’s FY23 results provide a recap of financial and operational highlights from the period. Following the restructuring announcement in January 2023, the company’s focus rests on its proprietary stem cell-derived exosome platform, CustomEx. In vivo animal studies to validate the platform’s capabilities are ongoing, and ReNeuron plans to release readout data in H2 CY23, which we anticipate could be a key catalyst and generate traction for partnerships. Due to the macroeconomic environment, m

Morning Note – 19 April 2023

FY22 results disappointing – outlook offers promise

FY22 was something of an annus horribilis for Abingdon due to factors largely outside of its control. As the pandemic has subsided, legacy issues have been resolved and management has cleared the decks for a reset of activities, focussing on a range of Contract Development and Manufacturing opportunities. The settlement with the DHSC has been resolved and £6.4m in cash received post-period end. Management therefore expects there to be no current funding requirement as it moves towards cashflow b

Positive preclinical data, interims and funding

Nuformix focusses on the development of NXP002, a patented novel form of tranilast. In a key step forward, completed preclinical studies support its future development. Most importantly, these studies indicate that tranilast, as prepared by Nuformix, can be dissolved and delivered to the lung by a nebuliser. Tranilast may be able to treat idiopathic pulmonary fibrosis (IPF, lung scarring) but needs to be in the lung in a higher dose than can be achieved orally - so direct lung delivery is crucia